Literature DB >> 22964770

Outcomes in women receiving low-molecular-weight heparin during pregnancy.

Maria T De Sancho1, Sana Khalid, Paul J Christos.   

Abstract

To assess the rate and type of maternal and infant complications among pregnant women receiving low-molecular-weight heparin (LMWH). Retrospective study of pregnant women on LMWH referred to two university hematology clinics from January 2001 to December 2010. We recorded the number of pregnancies, indication, dose and dose adjustments for LMWH, pregnancy outcomes (live births, maternal and infant complications) and side effects of LMWH. There were 89 pregnancies in 76 women. The most common indication for LMWH was a history of adverse outcome of pregnancy associated with thrombophilia. LMWH was adjusted in 75 and 45% of pregnancies in women on therapeutic and prophylactic doses, respectively. Live birth rate was 97%. There were 25 maternal and 11 infant complications. Side effects were minimal and included decreased bone mineral density and bleeding. LMWH use among pregnant women is associated with successful pregnancy outcomes. Although side effects were minimal, maternal and infant complications occurred in 28 and 12% of cases, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964770      PMCID: PMC4004025          DOI: 10.1097/MBC.0b013e328358e92c

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  22 in total

Review 1.  Hemodynamic changes in pregnancy.

Authors:  K L Thornburg; S L Jacobson; G D Giraud; M J Morton
Journal:  Semin Perinatol       Date:  2000-02       Impact factor: 3.300

2.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

3.  Recent trends and patterns in cesarean and vaginal birth after cesarean (VBAC) deliveries in the United States.

Authors:  Marian MacDorman; Eugene Declercq; Fay Menacker
Journal:  Clin Perinatol       Date:  2011-06       Impact factor: 3.430

Review 4.  Heparin-induced osteoporosis and pregnancy.

Authors:  Genevieve Le Templier; Marc A Rodger
Journal:  Curr Opin Pulm Med       Date:  2008-09       Impact factor: 3.155

5.  Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy.

Authors:  Rita Santoro; Piergiorgio Iannaccaro; Simona Prejanò; Gaetano Muleo
Journal:  Blood Coagul Fibrinolysis       Date:  2009-06       Impact factor: 1.276

6.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Shannon M Bates; Ian A Greer; Ingrid Pabinger; Shoshanna Sofaer; Jack Hirsh
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 7.  The use of low-molecular-weight heparins in pregnancy--how safe are they?

Authors:  Philippe Deruelle; Capucine Coulon
Journal:  Curr Opin Obstet Gynecol       Date:  2007-12       Impact factor: 1.927

Review 8.  Where do we go now with low molecular weight heparin use in obstetric care?

Authors:  J P Patel; B J Hunt
Journal:  J Thromb Haemost       Date:  2008-06-04       Impact factor: 5.824

9.  Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.

Authors:  Carl A Laskin; Karen A Spitzer; Christine A Clark; Mark R Crowther; Jeff S Ginsberg; Gillian A Hawker; John C Kingdom; Jon Barrett; Michael Gent
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

10.  Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.

Authors:  E Rey; P Garneau; M David; R Gauthier; L Leduc; N Michon; F Morin; C Demers; S R Kahn; L A Magee; M Rodger
Journal:  J Thromb Haemost       Date:  2008-11-20       Impact factor: 5.824

View more
  1 in total

1.  How can Secondary Thromboprophylaxis in High-Risk Pregnant Patients be Improved?

Authors:  Lucia Stanciakova; Miroslava Dobrotova; Pavol Holly; Jana Zolkova; Lubica Vadelova; Ingrid Skornova; Jela Ivankova; Matej Samos; Tomas Bolek; Marian Grendar; Jan Danko; Peter Kubisz; Jan Stasko
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.